The linking of protein sequence to function can be studied by using protein engineering and directed evolution techniques. It has served as a storage solution for both engineered plant proteins and exogenous proteins in plants. In protein engineering, the goal is to modify a protein sequence by adding, deleting, or modifying nucleotides, resulting in a customized protein more suitable for a particular function or application. In contrast, it focuses more on applications than targeted mutagenesis, altering specific sites within a gene sequence. Engineers can make such alterations to examine the effects of specific gene mutations in a cell, as in protein engineering.
It can be applied to enhance the affinity & efficacy of molecules for a wide range of applications, such as cardiac repair, by circumventing weaknesses associated with drugs. A significant increase in the adoption of these tools to develop advanced therapeutics has resulted from this, resulting in rapid market progression.
Register now and access 10 year Global market forecast data for 5 markets free.
Register now to get free 10 year market forecast of Protein Engineering Market research report
The advent of recombinant Monoclonal Antibodies (mAbs), for example, is the result of the extensive use of protein engineering tools. According to the market database, various cancers, transplant rejections, autoimmune diseases, and other conditions have improved with mAbs. The concept emerged through humanization and chimerization approaches.
The engineered molecules possess enhanced efficacy, reduced immunogenicity, and improved safety. In 1982, the United States FDA approved the first protein therapeutic developed through recombinant DNA technology, Humulin (human insulin). The ability to modify the specific function of a given drug molecule through protein engineering, as in the case of the modification of human butyrylcholinesterase substrate specificity, illustrates the potential of protein engineering for drug metabolism and medical science.
According to the market database, the high impact-rendering driver of the market is a rising urgency to curb high R&D costs in clinical trials. In preclinical development, high failure rates lead to increased costs. It usually takes several years for a new drug molecule to reach the market and become commercialized. In the early stage of clinical trials, approximately 50% of the compounds fail, which significantly increases the overall cost. The use of advanced software during preclinical development can surpass a few stages of drug discovery and development. In addition, regulatory authorities are constantly striving to reduce the time and cost involved in drug discovery. To incorporate advanced technologies into the drug discovery process, the FDA has launched the Critical Path Initiative.
Integral Molecular launches GeneCanvas
According to the market database, Integral Molecular launched a proprietary protein engineering platform called GeneCanvas. The platform optimizes transgenes and other elements essential for gene therapy development. It can improve the expression, trafficking, stability, and function of transgene proteins. As a result, there will be greater efficacy, smaller doses, and increased safety for patients.
A high-throughput mutagenesis platform and a human cells-screening platform are employed to build and screen libraries of variants. It analyzes each target in-depth to determine the best approach for protein engineering and develop a customized plan for the customer.
Using GeneCanvas‘ four deep-screening platforms, thousands of targeted mutations are created and screened for binding or functional activity in human cells. It involves using shotgun mutagenesis and comprehensive affinity mutagenesis. Millions of variations exist by random mutagenesis and flow cytometry to test binding in human cells. Bacteria can evolve in hundreds of different ways, and each variant strives for optimal activity. The high-affinity phage variants are selected using specialized phage protocols.
GenScript Biotech and Allozymes
According to the market database, Allozymes, a synthetic biology company that unlocks protein engineering potential through groundbreaking technologies, has partnered with GenScript Biotech Corporation. In this partnership, GenScript will construct mutant libraries for Allozymes’ downstream applications in various industries such as pharmaceuticals, cosmetics, and food and beverage.
Aside from the de novo gene synthesis capabilities, GenScript will leverage the cutting-edge semiconductor-based oligo synthesis technology to create a mutant library with an unbiased synthesis of thousands of variants to achieve the diverse and integrated mutant library.
It reduces overall downstream costs, speeds up discovery workflow, and saves valuable screening time. This partnership will leverage Allozymes’ patented screening platform to achieve significant breakthroughs in protein engineering research. The Protein Engineering market and its 10-year business outlook can be understood using Global Market Database.
